Biomedical Engineering Reference
In-Depth Information
Heide JB, Wathne KH (2006) Friends, businesspeople, and relationships roles: a conceptual frame-
work and a research agenda. J Market 70:90-103
Henry D, Doran E, Kerridge I, Hill S, McNeill PM, Day R (2005) Ties that bind: multiple relation-
ships between clinical researchers and the pharmaceutical industry. Arch Intern Med
165:2493-2496
Heugens PM, Lander MW (2009) Structure! agency! (and other quarrels): meta-analyzing institu-
tional theories of organization. Acad Manage J 52(1):61-85
Hill KP, Ross JS, Egilman DS, Krumholz HM (2008) The ADVANTAGE seeding trial: a review of
internal documents. Ann Intern Med 149:251-258
Insel TR (2010) Psychiatrists' relationships with pharmaceutical companies: part of the problem
or part of the solution. J Am Med Assoc 303(12):1192-1193
Jampol LM, Packer S, Mills RP, Day SH, Lichter PR (2009) A perspective on commercial relation-
ships between ophthalmology and industry. Arch Ophthalmol 127(9):1194-1202
Katz D, Kahn RL (1966) The social psychology of organizations. John Wiley and Sons, New York
Keteyian, Armen (2007) Big Pharma Courts Doctors, Available at
http://www.cbsnews.com/video/
Lampel J, Shamsie J (2000) Probing the unobtrusive link: dominant logic and the design of joint
ventures at general electric. Strat Manage J 21:593-602
Lawrence TB, Suddaby R (2006) Institutions and institutional work. In: Clegg SR, Hardy C,
Lawrence TB, Nord WR (eds) The Sage handbook of organization studies. Sage, London
Lewin AY, Volberda HW (1999) Prolegomena on coevolution: a framework for research on strat-
egy and new organizational forms. Organ Sci 10(5):519-534
Manchanda P, Chintagunta PK (2004) Responsiveness of physician prescription behavior to sales
force effort: an individual level analysis. Market Lett 15(2-3):129-145
Manchanda P, Honka E (2005) The effects and role of direct-to-physician marketing in the phar-
maceutical industry: an integrative review. Yale J Health Policy Law Ethics 5(2):785-822
March JG (1996) Continuity and change in theories of organizational action. Adm Sci Q
41(2):278-287
March JG, Olsen JP (1998) The institutional dynamics of international political orders. Int Organ
52(4):943-969
Mathews AW (2005) At medical journals, writers paid by industry play big role.
http://globalag-
ing.org/health/us/2005/ghostwriters.htm
. Accessed Oct 1, 2006
McFarland RG, Bloodgood JM, Payan JM (2008) Supply chain contagion. J Market 72:63-79
Mello MM, Messing NA (2011) Restrictions on the use of prescribing data for drug promotion.
N Engl J Med 365(13):1248-1254
Mizik N, Jacobson R (2004) Are physicians “easy marks”? quantifying the effects of detailing and
sampling on new prescriptions. Manage Sci 50(12):1704-1715
Moncrieff J, Hopker S, Thomas P (2005) Psychiatry and the pharmaceutical industry: who pays
the piper? A perspective from the critical psychiatry network. Psychiatrist 29:84-85
Moore DA, Tetlock PE, Tanlu L, Bazerman MH (2006) Confl icts of interest and the case of auditor
independence: moral seduction and strategic issue cycling. Acad Manage Rev 31(1):10-29
Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gøtzsche PC,
Bero LA (2002) Prevalence of honorary and ghost authorship in Cochrane reviews. J Am Med
Assoc 287:2769-2771
Murray MT (2010) What the drug companies Won't tell You and your doctor doesn't know: the
alternative treatments that may change your life-and the prescriptions that could harm You.
Atria Books, New York, NY
Narayanan S, Desiraju R, Chintagunta PK (2004) Return on investment implications for pharma-
ceutical promotional expenditures: the role of marketing-mix interactions. J Market
68(4):90-105
Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing
communication in new product categories. J Market Res 42:278-290
Search WWH ::
Custom Search